These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9873863)

  • 1. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates.
    Shen MC; Hu FC; Lin JS; Tsai W; Fon MF; Wang EC
    Haemophilia; 1998 Jan; 4(1):33-40. PubMed ID: 9873863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. I. Immunological associations with the consumption of factor concentrates.
    Ming-Ching S; Fuei-Yuen L; Yen-Ping K; Ron-Fon H
    Haemophilia; 1995 Oct; 1(4):243-8. PubMed ID: 27214631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement therapy with plasma-derived factor VIII concentrates induces skew in T-cell receptor usage and clonal expansion of CD8+ T-cell in HIV-seronegative hemophilia patients.
    Matsutani T; Sakurai Y; Yoshioka T; Tsuruta Y; Suzuki R; Shima M; Yoshioka A
    Thromb Haemost; 2003 Aug; 90(2):279-92. PubMed ID: 12888876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
    Teitel JM; Card R; Strawczynski H
    Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Thromb Haemost; 1995 Mar; 73(3):552-3. PubMed ID: 7667844
    [No Abstract]   [Full Text] [Related]  

  • 7. The choice of plasma-derived clotting factor concentrates.
    Mannucci PM
    Baillieres Clin Haematol; 1996 Jun; 9(2):273-90. PubMed ID: 8800505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y).
    Evans JA; Pasi KJ; Williams MD; Hill FG
    Br J Haematol; 1991 Nov; 79(3):457-61. PubMed ID: 1751373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factors isolated with monoclonal antibodies.
    Gomperts ED
    Curr Stud Hematol Blood Transfus; 1991; (58):52-8. PubMed ID: 1954774
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo.
    Higgins JA; Giangrande PL; Kernoff PB; Goodall AH
    Br J Haematol; 1993 Feb; 83(2):296-305. PubMed ID: 8457478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?
    Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K
    Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
    Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
    Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of the type of factor VIII concentrate on the CD4 lymphocyte count in hemophiliacs with human immunodeficiency virus infection: the results of a meta-analysis].
    Montoro Ronsano JB; Oliveras Martín J; Tusell Puigbert JM
    Med Clin (Barc); 1994 Nov; 103(18):690-4. PubMed ID: 7808075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates.
    Woelfle J; Berg T; Bialek R; Keller KM; Effenberger W; Wagner N
    Arch Dis Child; 1999 May; 80(5):429-32. PubMed ID: 10208947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunological and clinical parameters in HIV seronegative and seropositive hemophiliacs.
    Varon D; Schulman S; Dardik R; Barzilai A; Bashari D; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):359-62. PubMed ID: 7855784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
    McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
    Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of HIV infectivity and composition of factor VIII concentrates on the immunity of haemophiliacs positive for HIV antibodies.
    Allain JP; Frommel D; Bosser C; Gazengel C; Larrieu MJ; Sultan Y
    Vox Sang; 1987; 53(1):37-43. PubMed ID: 3116770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion of clotting factor concentrates in haemophilia.
    Gomperts ED
    Br J Haematol; 1992 Aug; 81(4):625. PubMed ID: 1390258
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.